Akebia Share Price

Akebia Share Price

NASDAQ: AKBA | Micro Cap | Healthcare
$0.41
+$0.01 (1.45%) Last updated on 19 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • About
  • Price history
  • FAQs

Akebia Stock Performance

Open
$0.40
Prev. Close
$0.40
Circuit Range
N/A
Day Range
$0.40 - $0.42
Year Range
$0.36 - $1.74
Volume
33,980
Average Traded
$0.41

Akebia Share Price Today

As of 19 November 2026, Akebia Therapeutics, Inc.'s share price is $0.41. The stock opened at $0.40, compared to its previous close of $0.40. During today's trading session, Akebia Therapeutics, Inc.'s share price traded between $0.40 and $0.42, with an average price of $0.41. Over the past 52 weeks, the stock has recorded a high of $1.74 and a low of $0.36. In terms of performance, Akebia Therapeutics, Inc.'s share price has declined by 60.35% over the last six months and is down 74.28% on a year-on-year basis.

Akebia Share Price Chart

Line chart of the Akebia price trend over the selected period. The price rose overall, ranging from 0.40 to 0.42, ending at 0.41.
$0.40$0.42
L
Show Current Price
H

Akebia Stock Fundamentals & Key Indicators

Market Cap
$104.51M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.16
Revenue (TTM)
$236.20B
Return On Equity (TTM)
-218.76%
Profit Margin
-2.27%
Debt to Equity
2.47
Quarterly Earnings Growth YoY
-17.24%

Akebia Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$57.62$53.54$49.13$36.90
Net Profit-$12.24-$9.05-$8.91-$14.35
Net Profit Margin-21.24%-16.90%-18.14%-38.89%
Income ChangeN/A26.06%1.55%-61.05%

Akebia Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$292.48$194.62$160.18$236.20
Net Profit-$94.23-$51.93-$69.41-$5.35
Net Profit Margin-32.22%-26.68%-43.33%-2.27%
Income ChangeN/A44.89%-33.66%92.29%

Akebia Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets123.61106.84123.55170.87
Current Assets252.96113.83118.15185.18
Total Assets376.57220.67241.7356.05
Non Current Liabilities181.02188.94172.42221.29
Current Liabilities162.9480.9199.87129.54
Total Liabilities343.96269.86272.29350.82
Shareholders' Equity32.61-49.19-30.585.23

Akebia Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating67.99-40.66-23.38-73.15
Investing-7.93-0.030.0-0.11
Financing72.9349.66-25.2114.6

About Akebia

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Akebia Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$0.71
$0.41
-42.13%
Oct 2026
$0.91
$0.70
-23.45%
Sep 2026
$0.92
$0.92
-1.92%
Aug 2026
$1.32
$0.94
-29.13%
Jul 2026
$1.16
$1.32
+17.78%
Jun 2026
$1.02
$1.13
+9.76%
May 2026
$1.40
$1.02
-25.99%
Apr 2026
$1.41
$1.39
-0.36%
Mar 2026
$1.28
$1.39
+5.30%
Feb 2026
$1.39
$1.32
-6.38%
Jan 2026
$1.60
$1.41
-12.15%
Dec 2025
$1.59
$1.60
+1.58%

Akebia Share Price FAQs